Defining Criteria for Guiding Cancer Patients to Find a Reputable Complementary Medicine Provider: Results of a Literature Review and a Consensus Procedure.
complementary medicine
healthcare quality assurance
neoplasms
patient-centered care
standards
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
09
2019
accepted:
14
02
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
epublish
Résumé
Even in cases of positive evidence for complementary medicine (CM) therapies, it is still difficult for cancer patients to identify reputable providers. The aim of this study was to develop and evaluate a criteria list to provide guidance to cancer patients seeking a reputable CM provider. The design combined a literature review, an expert consensus procedure (n=15) and an assessment from three stakeholder perspectives (patients (n=18), CM providers (n=26) and oncology physicians (n=20)). A total of 30 existing CM criteria were extracted from the literature, and 12 more were added by the experts. The main challenge was to define criteria that could easily be applied by the patients. A final comprehensive list of 8 criteria guiding cancer patients to find a reputable CM provider was developed. Health professionals and cancer information services might find the criteria list helpful when aiming to strengthen patients' awareness of quality-related factors associated with CM providers. The criteria developed might be helpful when standards are established for quality assurance in CM in oncology.
Identifiants
pubmed: 32368016
doi: 10.2147/PPA.S230705
pii: 230705
pmc: PMC7183350
doi:
Types de publication
Journal Article
Langues
eng
Pagination
747-755Informations de copyright
© 2020 Rogge et al.
Déclaration de conflit d'intérêts
Patrick Jahn reports grants, personal fees from Chugai, personal fees from Bristol-Myers Squibb, non-financial support from Helsinn, non-financial support from Tesaro, outside the submitted work. Petra Voiß reports grants from Carstens-Stiftung, during the conduct of the study. Claudia M. Witt reports personal fees, non-financial support from Several Swiss Hospitals, outside the submitted work. The authors report no other conflicts of interest in this work.
Références
Trials. 2019 Jan 29;20(1):90
pubmed: 30696465
Integr Cancer Ther. 2012 Sep;11(3):187-203
pubmed: 22019489
Ann Intern Med. 2017 Apr 4;166(7):514-530
pubmed: 28192789
Integr Cancer Ther. 2018 Sep;17(3):844-853
pubmed: 29629606
Forsch Komplementmed. 2016;23(3):174-8
pubmed: 27404102
Acta Oncol. 2017 Dec;56(12):1665-1676
pubmed: 28686520
Health Technol Assess. 1998;2(3):i-iv, 1-88
pubmed: 9561895
JAMA Oncol. 2018 Oct 1;4(10):1375-1381
pubmed: 30027204
Cochrane Database Syst Rev. 2017 Jan 03;1:CD010802
pubmed: 28045199
J Clin Oncol. 2018 Sep 1;36(25):2647-2655
pubmed: 29889605